There are limited data on the comparison of unrelated vs related peripheral blood-derived hematopoietic cell transplantation (HCT) in patients with AML and its implications in high-risk patients. In this single-center retrospective study, we report on a total of 92 consecutive patients with AML (n ¼ 87) or myelodysplastic syndrome (MDS; n ¼ 5), who were treated between 1996 and 2006 with a uniform preparative regimen of BU and CY and peripheral bloodderived HCT from related (n ¼ 46) or unrelated donors (n ¼ 46). At transplantation, 45 patients were in CR, 11 were untreated and 36 had relapsed or refractory disease. Median follow-up was 864 days after transplant (range 24-3798). At 5 years after HCT, cumulative incidences for relapse (32% of all patients) and nonrelapse mortality (NRM; 17%) were low. The 5-year relapse-free survival (RFS) and OS rates were 36 and 45% for related and 47 and 57% for unrelated patients, respectively (RFS P ¼ 0.43; OS P ¼ 0.28). High-risk patients with an unfavorable remission status before HCT benefited more from unrelated HCT than related HCT, showing a significantly better 5-year RFS of 46% (95% confidence interval (CI) 27-65) vs 22% (95% CI 4-40) (P ¼ 0.04). Unrelated HCT benefited high-risk AML patients with an unfavorable remission status better than related HCT.
Introduction
Complete remission is achievable with standard induction chemotherapy regimens in approximately 75% of adult patients o60 years of age with cytogenetically normal AML. Yet, approximately 55% of patients are in CR relapse. A recent report by Schlenk et al. 1 shows a median relapse-free survival (RFS) and OS of 22 months and 30 months, respectively, in patients with cytogenetically normal AML. In comparison with high-dose cytarabine, postremission HCT can reduce the risk of relapse. 2, 3 In the study by Schlenk et al., 1 after remission, related allogeneic HCT prolonged the RFS rate significantly compared with standard chemotherapy. They showed a hazard ratio of 0.6 for the risk of relapse or death during CR. The benefit of transplantation was limited to the subgroup of patients with a prognostically adverse genotype.
The most important negative risk factors influencing outcome after HCT seem to be an advanced stage of disease or relapse before HCT, or the presence of unfavorable cytogenetics and specific genetic mutations. [2] [3] [4] [5] Other currently recognized risk factors associated with a worse outcome include older age and development of acute or chronic GVHD. [6] [7] [8] The aim of this single-center retrospective study was to review the clinical characteristics and evaluate the potential predictors of RFS and OS in unrelated vs sibling donor HCT. Therefore, we analyzed the data of 92 consecutive adult patients with AML and myelodysplastic syndrome (MDS) undergoing their first peripheral blood-derived HCT from related or unrelated donors at the University of Freiburg Medical Center between 1996 and 2006 after treatment with a uniform preparative regimen consisting of high-dose oral BU and CY. All patients received a cyclosporine and MTX-based GVHD prophylaxis. Our analysis focused on comparing unrelated with sibling donor HCT for differences in nonrelapse mortality (NRM) and outcome, especially in a high-risk situation. As there are limited data on unrelated HCT derived from peripheral blood rather than BM in high-risk patients with myeloid malignancies, we believe this analysis to be of considerable interest.
Taken together, we were able to show a better outcome after unrelated HCT in patients with advanced disease.
Patients and methods
Patient and graft characteristics are shown in Table 1 . In all, 87 patients with AML, including secondary AML and therapy-associated AML, and five patients with primary MDS received HCT from a related (n ¼ 46) or HLA-A, -B or -DR matched (n ¼ 38) or mismatched (n ¼ 8) unrelated donor (n ¼ 46). All patients gave informed consent, and all received a uniform conditioning regimen consisting of BU 4 Â 1 mg/kg body weight (b.w.) per day administered orally for 4 consecutive days (days À7 to À4) and CY 60 mg/kg b.w. per day i.v. for days À3 and À2. Three patients received additional chemotherapy before transplant the week before conditioning because of high disease burden as described previously. 9 GVHD prophylaxis consisted of a cyclosporine-and MTX-based protocol (cyclosporine 5 mg/ kg b.w. per day, starting day À3, targeted through serum level; MTX 15 mg/m 2 on day þ 1, 10 mg/m 2 on days þ 3 and þ 6). In 18 related and 26 unrelated patients, we reduced the MTX dose because of advanced disease before HCT (MTX 5 mg/m 2 day þ 1, þ 3, þ 6 when not in CR1). Until 1998, nine patients received prednisone as well. Anti-T-lymphocytic globulin, manufactured by Fresenius (ATG-F; Graefelfing, Germany), was added in unrelated donor HCTs performed in patients in CR1 or in a mismatch situation (60 mg/kg b.w.), and in patients not in CR1 (40 mg/kg b.w.). Results of cytogenetic analyses of cells aspirated from BM were obtained from 95% of patients at the time of diagnosis or immediately before HCT. Patients were classified into those with a normal karyotype, that is, having with one or two cytogenetic abnormalities, and those with a complex karyotype, that is, having three or more cytogenetic alterations. Ten patients (n ¼ 4 related and n ¼ 6 unrelated recipients) had a cytogenetic alteration on chromosome 7.
The remission status of patients at HCT was determined using morphological criteria. All patients were treated using institutional transplant guidelines for antimicrobial, antifungal and antiviral prophylaxis. 9 Transfusion support was given to maintain hemoglobin levels 48 g per 100 ml and plt counts 410 000/ml. Acute GVHD was clinically graded as 0-IV on the basis of standard published criteria; 10 chronic GVHD was classified as none, limited or extensive.
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Statistical analysis Data analysis was performed using the SAS system version 9 (SAS Institute, Inc., Cary, NC, USA). OS was defined as time from HCT until death from any cause, and RFS was calculated as time from HCT to death from any cause or relapse, whichever occurred first. For those patients not experiencing the event in question for OS or RFS during follow-up, time to last contact was used as a censored observation. The Kaplan-Meier method was used to estimate RFS and OS probabilities. The effect of potential prognostic factors on OS was investigated using Cox proportional hazards models. Univariate models were considered first, and then a multivariate model was constructed with factors that revealed a univariate significance level of a ¼ 0.30 and that remained in the model after application of a backward elimination strategy with a significance level of a ¼ 0.10. Results are presented as hazard ratios with two-sided 95% confidence intervals (CIs). Rates of relapse mortality were estimated as cumulative incidence rates, in which death without relapse was considered as a competing risk. Similarly, GVHD rates (acute and chronic) were analyzed using cumulative incidence rates, in which death without GVHD is regarded as a competing risk. Improved outcome after unrelated allogeneic HCT in high-risk AML U Denz et al
Results

Engraftment, transplantation toxicity and infections
Conditioning chemotherapy was administered according to protocol; the dose of BU had to be reduced in two patients because of convulsions or impaired liver function. Two patients showed severe liver toxicity and one showed additional skin toxicity. ATG-F caused allergic side effects in four patients and hemolysis in one patient. Until March 2004, G-CSF was applied, starting on day þ 7 (66 patients), and thereafter it was omitted according to protocol (25 patients); one patient received G-CSF starting on day þ 1. All patients were engrafted with leukocytes 41 Â 10 9 /l on median day þ 12 (range days 9-30). Unsupported plt counts of 420 Â 10 9 /l were achieved on median day þ 13 (range 8-79). One patient died before plt engraftment after unrelated HCT because of severe liver toxicity, GVHD and sepsis. Other early nonrelapse-related deaths (before day þ 100) were because of suspected cardiac infarction or pulmonary aspergillosis. Thus, cumulative NRM (Figure 1 ) at day þ 100 was 3.3% (n ¼ 3) for the whole cohort.
Infectious complications after day þ 100 were bacterial pneumonia in five patients and viral pneumonia in one patient. Sepsis as the primary cause of death was documented in five patients. CMV reactivations, defined by positive blood CMV antigenemia or negative PCR, occurred in 15 related (33%) and 26 unrelated (57%) patients. The risk of CMV reactivation, when considering patient and donor CMV serostatus constellations, was higher in the unrelated group (Table 1) . Herpes zoster infection of the skin was recorded in one unrelated and five related patients. Pulmonary aspergillosis occurred in four related and three unrelated patients; it was fatal in two related and two unrelated patients and existed before transplant in two patients. Tuberculosis occurred in two patients, one of whom died. Two patients in CR had a late secondary skin malignancy (basalioma).
GVHD
The cumulative incidence of acute GVHD 1II-1IV at day þ 100 for related vs unrelated HCT was 18 vs 28% with a univariate Cox regression, hazard ratio (95% CI) of 0.57 (0.24-1.37), P ¼ 0.21 (Table 2a) . One unrelated patient died of acute GVHD 1IV before day þ 100. Eight patients with acute GVHD 1III-1IV died after day þ 100, five patients because of progressive disease and three because of infectious complications. Among 45 related and 43 unrelated patients who were alive at day þ 100, we documented limited chronic GVHD in five related (11%) and 12 unrelated (28%) patients. The cumulative incidence of chronic extensive GVHD at 3 years for related vs unrelated HCT was 44 vs 33% with a univariate Cox 92  68  51  40  31  21  12  5  3  2  1 Cum. incidence rate Figure 1 Cumulative incidences of relapse and nonrelapse mortality (NRM) in all patients. The x axis shows months from HCT; -cumulative incidence of relapse; -----cumulative incidence of NRM. Abbreviations: NRM ¼ non-relapse mortality; RFS ¼ relapse-free survival.
Improved outcome after unrelated allogeneic HCT in high-risk AML U Denz et al regression, hazard ratio (95% CI) of 1.51 (0.77-2.95), P ¼ 0.23 ( Figure 2b ). The median interval from transplantation to onset of chronic GVHD was 157 days (range 80-1135 days).
Outcome
As of January 2007, median follow-up was 864 days (range 24-3798 days). In all, 52 patients (56.5%) were alive, 43 of whom were in sustained CR (Table 2a) ; two additional patients were in hematological CR but with mixed chimerism. A total of 37 patients suffered a relapse (including 14 patients in CR at HCT), 28 of whom died. Eight patients had a relapse involving the central nervous system, including four patients with an isolated central nervous system relapse. These four patients were alive at the end of the observation in contrast to patients with a systemic relapse as well. Overall, 40 patients died, 27 from relapse and 13 from NRM. At 5 years, the cumulative incidence of relapse of all patients was 32% (95% CI 24-44), and of NRM, 17% (95% CI 10-28) (Figure 1 Figure 3a ) and for OS at 45% (95% CI 28-61) vs 57% (95% CI 41-72) (P ¼ 0.28; Figure 3b ), respectively. The number of cytogenetic abnormalities did not reveal a significant disadvantage regarding transplantation outcome. Pre-transplant remission status has a significant influence on transplantation outcome. Estimated 5-year RFS for and b) . These results are reflected in cumulative incidences of relapse mortality at 5 years after transplant of 53% (95% CI 36-79) after related and 23% (95% CI 11-48) after unrelated HCT in patients not in CR1 at transplantation (P ¼ 0.031). In that subgroup, the cumulative incidences of NRM were 13% (95% CI 5-37) for related and 24% (95% CI 12-48) for unrelated HCT (P ¼ 0.7). A total of 36% of related patients (vs 53% of unrelated patients) with pretransplant circulating blasts were alive at the end of our observation period. Patients in CR1 did not show significantly different RFS or OS rates when related and unrelated HCTs were compared. We also conducted a multivariate analysis of factors influencing OS, showing a positive influence on OS for patients in CR1 with regard to pre-transplant remission status, unrelated HCT, male donor and patient age o45 years at HCT (Table 2b) .
Discussion
In this study, we present a data analysis of a large patient cohort with a uniform high-dose myeloablative BU/CY conditioning regimen that received an allogeneic peripheral blood-derived graft HCT for myeloid hematologic malignancies. Thirteen patients in our cohort died of nonrelapse causes. Some complications may be related to the disease course before transplantation, including colonization with infectious organisms or cumulative toxicity. Our 5-year incidence of NRM of 17% for all patients is low when compared with previous reports, which reveal NRM rates between 22% in related and 43% in unrelated HCT recipients after myeloablative conditioning. 5, 12 All patients received a cyclosporine and MTX-based GVHD prophylaxis, and unrelated patients also received ATG-F. The GVHD rates compare favorably with results obtained with a standard cyclosporine and MTX regimen as already published. 13, 14 Persistent, extensive chronic GVHD was apparent in 21% of surviving patients at the time of data analysis. A previously published study observed 34% persistent, extensive chronic GVHD after unrelated BM HCT, resulting in a lower performance status and quality of life. 12 The relatively low rate of severe acute GVHD and persistent chronic GVHD in unrelated patients might be attributable to the successful use of ATG-F, as reported by our group. 15 In particular, the successful use of ATG-F might be reflected in the lower (although not statistically significant) rate of chronic extensive GVHD after unrelated HCT compared with related HCT. It is noteworthy that, on taking into account the lower relapse risk after unrelated HCT compared with related HCT, a clinically significant negative influence on the GVL effect by ATG-F could not be observed. In this context, different doses and time schedules of ATG application seem to be relevant. It is worth noting that with the use of ATG-F, the duration and extent of T-cell suppression could be favorable, associated with fewer infectious complications compared with trials using different ATGs. 16 ATG-F is now being investigated in a randomized multicenter trial. 17 After a median follow-up of 864 days, 56% of patients were alive, 43 of whom were in sustained CR. This reflects the 5-year RFS and OS rates of 42 and 51%, respectively, for all patients. These results are consistent or even superior to those of published reports using myeloablative regimens, 15, [18] [19] [20] and are particularly encouraging considering that 51% of patients were not in CR at HCT, 24% patients had over 20% blasts in the BM and 27% presented blasts in the peripheral blood. Previous studies reported OS rates of 20-30% in refractory AML using standard conditioning regimens for HCT. 21, 22 In our study, the incidence of relapse at 5 years was low (32% for all patients). This is comparable with published reports in advanced AML and MDS patients, or AML patients in remission with unfavorable cytogenetics. 18, 23, 24 In our study, it was somewhat surprising that cytogenetic abnormalities did not Improved outcome after unrelated allogeneic HCT in high-risk AML U Denz et al reveal a significant effect on outcome. Most probably, this can be explained by the limited data on patient cytogenetics in the studied cohort. Multivariate analysis showed a significant unfavorable influence for female vs male donors. This statistical effect may be because of the coincidence that 31 patients with a male donor but only 13 patients with a female donor were in CR at HCT. Eight patients had a relapse involving the central nervous system; interestingly, six of them had no acute GVHD. Although one would have little expectation that GVHD would affect recurrence in the privileged central nervous system site, Lee et al. 25 reported an increased risk of specific medullary in contrast to systemic relapse in the absence of acute GVHD.
In addition, pre-transplant remission status had a significant effect on OS and RFS when comparing patients in CR1 with others. The relapse risk at 5 years after transplantation was 27% for patients in CR1 and 36% for those with an unfavorable remission status before transplant. These results are similar to previously published results in AML and MDS. [26] [27] [28] Our results did not reveal significant differences in RFS or OS when related HCT was compared with unrelated HCT in the entire cohort. The RFS and OS rates of patients in CR1 did not differ either, while comparing related with unrelated HCT. This observation may partly be because of the fact that most of those in CR1 undergoing an unrelated HCT were highrisk patients with high-risk factors, for example, unfavorable cytogenetics. Thus, some of the results may be influenced by a selection of patients in different risk groups for different times of transplantation.
Subgroup analysis among high-risk patients (not in CR1) did reveal a significantly better RFS for unrelated vs related transplantation. Although OS rates did not reach statistical significance, which might be explained by the limited number of 36 patients in this subgroup, these results show a clear benefit for unrelated HCT compared with related HCT in high-risk patients. This accounts for the lower relapse mortality and similar NRM. These findings are in contrast to that of Ringden et al. 29 In that retrospective study of 1611 AML patients (1271 matched sibling and 340 unrelated donor recipients), patients were more likely to experience relapse and lower RFS after unrelated donor transplantation (early and advanced disease) compared with matched sibling HCT. The different results between the study by Ringden et al. 29 and ours may be attributable in part to a high percentage of BM-derived grafts in the latter. Peripheral blood-derived grafts, as opposed to BMderived grafts, have been shown to be advantageous in terms of a faster hematopoietic and immune reconstitution. 30 Furthermore, although not statistically significant, Ringden et al. 29 observed a higher RFS in unrelated recipients compared with related HCT in patients with acute GVHD in contrast to patients without acute GvHD. In addition, in that study, NRM accounts for more deaths than does disease relapse, and unrelated recipients had a higher NRM than related transplant recipients. All these points, together with less experience in unrelated HCT, may attribute to the observed differences, certainly when considering that data from more than 500 transplant centers and as early as 1995 were included in the study by Ringden. In addition, unrelated HCT might have been carried out at a different time point in the disease course compared with related HCT. Although one should await the results of a large randomized study comparing unrelated and related HCT in high-risk patients, our results show an excellent outcome for this very challenging patient population. Certainly, our results must be interpreted with caution because of the retrospective nature of this analysis and the limited number of patients. Nevertheless, the need for an early initiation of a donor search is reflected. In addition, there seems to be no reason for delaying allografting in patients with high-risk AML or MDS if 'only' a suitable unrelated donor can be identified. Furthermore, the question can be raised whether selecting an unrelated donor over a related donor in very high-risk patients might have a benefit. The recently published results of Schetelig et al. 31 strongly support this hypothesis. In conclusion, we present data from a large patient cohort that received a uniform myeloablative BU and CY conditioning regimen and underwent peripheral bloodderived allogeneic HCT for myeloid hematologic malignancies. Patients with advanced disease had a better outcome after unrelated HCT than did those with related donors.
